helocyte inc private company information  bloomberg july    pm et pharmaceuticals company overview of helocyte inc snapshot people company overview helocyte inc engages in the development and commercialization of immunotherapies for the prevention and treatment of cytomegalovirus or cmv cancer and infectious disease it focuses on developing pepvax a hlarestricted single antigen peptide vaccine for controlling cmv in allogeneic hematopoietic stem cell transplant recipients and triplex a universal recombinant viral vector vaccine expressing three immunodominant proteins such as ul pp ul ie and ul ie linked to cmv in the posttransplant setting and pentamer a universal recombinant viral vector vaccine designed to induce a neutralizing antibody response to prevent the transmission of cmv from mother to fetus helocyte inc engages in the development and commercialization of immunotherapies for the prevention and treatment of cytomegalovirus or cmv cancer and infectious disease it focuses on developing pepvax a hlarestricted single antigen peptide vaccine for controlling cmv in allogeneic hematopoietic stem cell transplant recipients and triplex a universal recombinant viral vector vaccine expressing three immunodominant proteins such as ul pp ul ie and ul ie linked to cmv in the posttransplant setting and pentamer a universal recombinant viral vector vaccine designed to induce a neutralizing antibody response to prevent the transmission of cmv from mother to fetus helocyte inc was formerly known as diavax biosciences inc the company was founded in  and is based in new york new york helocyte inc operates as a subsidiary of fortress biotech inc detailed description  gansevoort streetth floornew york ny united statesfounded in  phone  wwwhelocytecom key executives for helocyte inc mr frank taffy jd cofounder chief executive officer president and director dr lindsay allan rosenwald md executive chairman of the board of directors age  don j diamond phd cofounder and chairman of scientific advisory board mr david jay horin cpa interim chief financial officer age  ms elizabeth moore executive vice president of regulatory affairs age  compensation as of fiscal year  helocyte inc key developments helocyte inc presents at aegis capital corp  growth conference sep  pm sep   helocyte inc presents at aegis capital corp  growth conference sep  pm venue the encore at wynn las vegas  las vegas blvd las vegas nv  united states helocyte presents at th annual roth conference mar  pm feb   helocyte presents at th annual roth conference mar  pm venue the ritz carlton  ritz carlton drive laguna niguel dana point california united states similar private companies by industry company name region st order pharmaceuticals inc united states st century animal health united states  buds organics llc united states p therapeutics llc united states ° pharmaceuticals llc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact helocyte inc please visit wwwhelocytecom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close helocyte inc careers site map about us overview senior management team board of directors product portfolio marketed products product pipeline publications business development contact fortress companies avenue therapeutics caelum biosciences cellvation checkpoint therapeutics cyprium therapeutics escala therapeutics helocyte inc journey medical mustang bio inc investors corporate information corporate profile senior management board of directors corporate presentations press releases events  webcasts stock information governance governance documents committee charting sec filings documents section  filings annual meeting materials other information information request email notification contact us fortress companies avenue therapeutics caelum biosciences cellvation checkpoint therapeutics cyprium therapeutics escala therapeutics helocyte inc journey medical mustang bio home » fortress companies » helocyte inc helocyte inc helocyte inc was formed to develop novel immunotherapies for the prevention and treatment of cytomegalovirus cmv a common virus that is typically asymptomatic in healthy individuals but can cause lifethreatening disease in those with weakened or uneducated immune systems the licensed immunotherapies were developed in the laboratory of don j diamond phd chair of the department of experimental therapeutics at city of hope national medical center in duarte california under the terms of the agreement with city of hope helocyte secured exclusive worldwide rights to two tcell immunotherapeutic vaccines for controlling cmv in stem cell and solid organ transplant recipients pepvax is an hlarestricted vaccine for which we are currently enrolling a multicenter phase ii clinical study of cmv control in allogeneic hematopoietic stem cell transplant hsct recipients triplex is a universal vaccine for which we are currently enrolling a phase ii clinical study of cmv control in allogeneic hsct recipients both programs are supported by grants from the national cancer institute  helocyte further secured exclusive worldwide rights to pentamer a universal vaccine that induces a broad neutralizing antibody response to prevent transmission of cmv in utero the most common congenital infection pentamer is currently undergoing preclinical development fortress biotech owns  of helocyte inc for more information please visit wwwhelocytecom  copyright  fortress biotech all rights reserved privacy policy disclaimer     download our app today helocyte trademark of helocyte inc serial number   trademarkia trademarks apply online attorneys services us trademark registration service international trademark registration service trademark office action response trademark statement of use trademark renewal trademark assignment trademark watch trademark cease  desist trademark comprehensive search copyright registration patent services incorporation services business page creation more services help contact us login trademark search trademark category computer  software services  scient helocyte   get free email alerts helocyte trademark information helocyte inc development of pharmaceutical preparations and medicines pharmaceutical research and development biotechnology research and development biopharmaceutical research and development provision of scientific research information in the field of pharmaceuticals and clinical trials perfect for these industries computer  software services  scientific services words that describe this mark development   pharmaceutical   preparations   medicines   pharmaceutical   research   development   biotechnology   research   development   biopharmaceutical   research   development   provision   scientific   research   information   field   pharmaceuticals   clinical   trials   this is a brand page for the helocyte trademark by helocyte inc  in new york ny  write a review about a product or service associated with this helocyte trademark or contact the owner helocyte inc of the helocyte trademark by filing a request to communicate with the legal correspondent for licensing use andor questions related to the helocyte trademark on wednesday july   a us federal trademark registration was filed for helocyte by helocyte inc new york ny  the uspto has given the helocyte trademark serial number of  the current federal status of this trademark filing is registered the correspondent listed for helocyte is devon e white of wyrick robbins yates  ponton llp  lake boone trl ste  raleigh nc   the helocyte trademark is filed in the category of computer  software services  scientific services  the description provided to the uspto for helocyte is development of pharmaceutical preparations and medicines pharmaceutical research and development biotechnology research and development biopharmaceutical research and development provision of scientific research information in the field of pharmaceuticals and clinical trials word mark helocyte statusstatus date registered  serial number  filing date  registration number  registration date  goods and services development of pharmaceutical preparations and medicines pharmaceutical research and development biotechnology research and development biopharmaceutical research and development provision of scientific research information in the field of pharmaceuticals and clinical trials mark description not available type of mark service mark published for opposition date  last applicantowner helocyte incnew york ny  why is this contact information displayed why is this contact information displayed close the uspto makes this data available for search by the public so that individuals can locate ownership information for intellectual property much the same way a county might make real estate property ownership information available since our website is synchronized with the uspto data we recommend making any data changes with the uspto directly our website will autoupdate when the uspto data is updated you may also contact trademarkia to make a request for the removal of your personally identifiable information or trademark data such requests must be made in writing and will be subject to verification of ownership this policy allows verified trademark owners to specify a that their identifiable information be masked or b that their trademark pages permanently deleted from trademarkiacom requests may be made directly to customerservicetrademarkiacom and every effort will be made to honor them within  hours click here for further details close mark drawing code standard character mark design search no data register type principal disclaimer not available correspondent devon e white wyrick robbins yates  ponton llp  lake boone trl ste  raleigh nc  use in commerce trademark  applicant has provided proof of use of this mark in commerce to uspto classification information primary class class   scientific and technological services and research and design relating thereto industrial analysis and research services design and development of computer hardware and software first use anywhere  first use in commerce  trademarkia is the largest search engine for us trademarks each month hundreds of trademarks around the world are filed by licensed attorneys in the legalforcetrademarkia network you can register your trademark in  countries in the world through legalforce network legalforce network can help you incorporate a business around your helocyte trademark in less than  minutes trademarkia makes the process easy and convenient so start now trademarkiacom is a free search engine of publicly available government records trademarkiacom is not a law firm and does not represent owners  correspondents listed on this page trademark document retrieval  trademark  apply online  satisfaction guarantee protect your valuable brand now how it works what you get  legalforce rapc   us trademark filing from  to now  describe how your business or product is being used register your mark in  countries just   govt fees start here   top global ip attorneys  credibility and experience  all processes will be performed in a timely manner you will be informed periodically about the process keep track of this brand trademark watch services keep track of how your trademark is being used available in the united states and in more than  countries roundtheclock monitoring monthly report on potential infringement watch this trademark trademark watch services read more current trademark status  registered free trademark search correspondent search devon e white is a correspondent of helocyte trademark current overall rating  review what you can do start your business free logo creator add to favorites view documents free trademark search start trademark filing process protect this mark internationally custom logo design  search helocyte on popular social networks trademarkia lets you see how your personal name product name trademark name or username is being used on any of  new and popular social networks be the first to reserve your name and get help stopping others from using it  all in one place trademark oppose service you can request for extension of time to oppose this mark or oppose it now  if you are new to legalforcetrademarkia please just enter your contact email and create a password  if you already have a legalforcetrademarkia account please enter your accounts email and password  email address please enter your email address  enter password please enter your password  please enter the value       status update alerts status update alerts are email updates of the latest trademark status change please make sure you provide the correct email  if you are new to legalforcetrademarkia please just enter your contact email and create a password  if you already have a legalforcetrademarkia account please enter your accounts email and password  email address please enter your email address  enter password please enter your password  please enter the value       review  rating please rate and review for helocyte helocyte is providing development of pharmaceutical preparations and medicines pharmaceutical research and development biotechnology research and development biopharmaceutical research and development provision of scientific research information in the field of pharmaceuticals and clinical trials  if you are new to legalforcetrademarkia please just enter your contact email and create a password to be associated with your review if you already have a legalforcetrademarkia account please enter your accounts email and password before posting your review  please rate        your review please enter your review  email address please enter your email address  enter password please enter your password       microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft helocyte – a fortress biotech company helocyte inc “helocyte” a portfolio company of fortress biotech inc is focused on the development and commercialization of novel immunotherapies for the prevention and treatment of cancer and infectious disease in particular cytomegalovirus or “cmv” press releases october   data from phase  trial of triplex vaccine for control of cytomegalovirus published in blood april   helocyte announces corporate and clinical milestones april   fortress biotech fka coronado biosciences forms new subsidiary helocyte inc fka diavax biosciences to develop novel immunotherapies for cytomegalovirus pipeline helocyte inc  company profile  biocentury publications archives bciq conferences version  free trial  subscribe sign in english   한국어 biocentury menu home  publications  publications home  biocentury bc innovations bc extra bc week in review current issues archives  archives home  basic search advanced search back issues bciq  bciq home  overview pipeline analyst financial analyst company analyst deal analyst conferences  conferences home  newsmakers bio€quity europe future leaders china healthcare summit other industry events elearning  elearning home  videos white papers follow us bciq  company profile bciq overview      settings      support biocentury print this       helocyte inc print preview export bookmark share with colleague general information  location new york ny  region new york state  country us  business category infectious cancer  year founded   website httpwwwhelocytecom  lead product status phase ii  archive items are loading  financial information  financing summary  financing details  earnings summary  stocks annual chart  pipeline information  pipeline summary  pipeline details  deals information  deals summary  deals details about biocentury company overview management editorial  research contact contact us advertising  sponsorship career opportunities support forgot password customer service reprints faqs products  solutions products overview publications archives bciq conferences elearning rss feeds legal user agreement terms of use privacy policy your california privacy rights use of images follow us what is biocentury biocentury employs a fully integrated multimedia platform — including publications video online data solutions and conferences — to provide its audience with authoritative and uptodate intelligence about corporate strategy partnering emerging technology clinical data public policy and the financial markets sign in free trial   biocentury inc all rights reserved    terms  conditions  privacy policy set email alert dummy bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one helocyte inc new york ny   ypcomstart your search by typing in the business name below what do you want to find wheremy current locationsearchhomepharmaceutical productswholesale  manufacturers near new york nyhelocyte incin mybook®  other collection editadded to your other collectionremoved from mybookwe took this business out of your other collectionhelocyte incwrite a reviewadd a photobe the first to review gansevoort st new york ny  add hoursadd to mybookthis listing has been added to mybookthis listing has been removed from mybookvisit websitesuggest an editis this your business customize this pageclaim this businesssponsored linkshoursdo you know the hours for this businessneighborhoodswest village downtown manhattanakamustang bio incother linkshttphelocytecomhttpmustangbiocomcategorypharmaceutical productswholesale  manufacturers coupons  dealsno coupons availablegallerybe the first to add a photoadd a photoreviewshi therebe the first to reviewfirstclassbetter than mostabout what i expectednot the worstdisappointingclick to rateshare reviewlike this review share it on your social network to get the word outsharetweetsharewant to just link to it instead copy url above and paste awaysponsored linksmap  directionspeople also viewedcreativeagent w th st new york nybristolmyers squibb co park ave new york nypurdue pharma lp th ave new york nyalife pharmaceutical inc w th st new york nyquest diagnostics greenwich ave new york nypaid advertisement we just redesigned ypcom do you like it× likenot a fan× thank youfeedback helocyte announces corporate and clinical milestones nasdaqfbio english français register sign in helocyte announces corporate and clinical milestones april    et  source helocyte inc frank taffy appointed president and chief executive officerlead immunotherapies pepvax and triplex advanced into phase  triplex phase  data presented at ashpepvax phase b data published in the lancet new york april   globe newswire  helocyte inc a majorityowned subsidiary of fortress biotech inc nasdaqfbio focused on the acquisition development and commercialization of novel immunotherapies for the prevention and treatment of cancer and infectious disease and in particular cytomegalovirus or “cmv” today announced several corporate and clinical milestones in june  helocyte’s board of directors appointed frank taffy as president and chief executive officer and in december  as an additional member of the board mr taffy has more than fifteen years of experience in life sciences corporate development and business operations he identified the helocyte programs and cofounded the company during his role as entrepreneur in residence at fortress biotech mr taffy previously held the positions of head senior director of business affairs at forest laboratories now allergan and director of corporate development at life technologies now thermo fisher scientific where he also held board positions on behalf of the company mr taffy began his career as counsel for intellectual property at procter  gamble he holds a jd from syracuse university college of law and a ba in biochemistry from the university of north texas in june  a phase  study of helocyte’s pepvax opened for enrollment the randomized placebocontrolled multicenter trial will evaluate the potential of pepvax to reduce the frequency of cmv events in  recipients of allogeneic hematopoietic stem cell transplant the study is supported by funding from the national cancer institute for additional information on the phase  study of pepvax please visit httpsclinicaltrialsgovctshownct  in november  a phase  study of helocyte’s universal triplex opened for enrollment the randomized placebocontrolled multicenter trial will evaluate the potential of triplex to reduce the frequency of cmv events in  recipients of allogeneic hematopoietic stem cell transplant the study is also supported by funding from the national cancer institute for additional information on the phase  study of triplex please visit httpsclinicaltrialsgovctshownct in november  the results of a phase  study of triplex were selected for presentation at the th annual meeting of the american society of hematology ash triplex is the first cmv immunotherapy that uses a recombinant modified vaccinia ankara mva vector incorporating multiple cmv response antigens the phase  study demonstrated the safety and marked immunogenicity of triplex the complete text of the ash abstract can be accessed at httpsashconfexcomashwebprogrampaperhtml in december  the results of a phase b study of pepvax were published in the lancet haematology pepvax was observed to be welltolerated immunogenic and highly effective in controlling cmv in patients to our knowledge pepvax is the first immunotherapy to demonstrate proof of concept for cmv control in the posttransplant setting pepvax further demonstrated the unexpected clinical outcomes of reduced relapse and increased survival from underlying cancer the full text of the lancet publication can be accessed at httpwwwthelancetcomjournalslanhaearticlepiisxabstract about helocytehelocyte is a clinicalstage company developing novel immunotherapies for the prevention and treatment of cancer and infectious disease and in particular cytomegalovirus or “cmv” the centers for disease control estimate that  to  percent of americans are infected with cmv by the age of  while the virus is asymptomatic in healthy individuals it can cause severe and lifethreatening disease in those with weakened or uneducated immune systems patients undergoing allogeneic stem cell and solid organ transplantation are at particularly high risk of experiencing complications associated with cmv helocyte’s pepvax and triplex vaccines are engineered to induce a robust and durable virusspecific t cell response to control cmv in transplant recipients helocyte’s pentamer vaccine is designed to induce a neutralizing antibody response to prevent the transmission of cmv from mother to fetus the most common congenital infection there is no approved therapy for the prevention or treatment of congenital cmv while current antiviral therapies have reduced the rate of cmv diseaserelated mortality in transplant recipients such treatments have been linked to increased toxicity delayed immune reconstitution and late onset of cmv the helocyte vaccines can educate the body’s innate immune system to fight cmv for more information please visit wwwhelocytecom about fortress biotechfortress biotech inc “fortress” or “the company” is a biopharmaceutical company dedicated to acquiring developing and commercializing novel pharmaceutical and biotechnology products  fortress plans to develop and commercialize products both within fortress and through subsidiary companies also known as fortress companies  in addition to its internal development programs the company will leverage its biopharmaceutical business expertise and drug development capabilities to help the fortress companies achieve their goals  additionally the company will provide funding and management services to each of the fortress companies and from time to time the company and the fortress companies will seek licensing partnerships joint ventures andor public and private financings to accelerate and provide additional funding to support their research and development programs for more information visit wwwfortressbiotechcom forwardlooking statementsthis press release may contain “forwardlooking statements” within the meaning of section a of the securities act of  and section e of the securities exchange act of  such statements include but are not limited to any statements relating to our growth strategy and product development programs and any other statements that are not historical facts forwardlooking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business operating results financial condition and stock price factors that could cause actual results to differ materially from those currently anticipated are risks related to our growth strategy our ability to obtain perform under and maintain financing and strategic agreements and relationships risks relating to the results of research and development activities uncertainties relating to preclinical and clinical testing including the risk that clinical data will not be reproduced in larger studies our dependence on third party suppliers our ability to attract integrate and retain key personnel the early stage of products under development our need for substantial additional funds government regulation patent and intellectual property matters competition as well as other risks described in our sec filings we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events conditions or circumstances on which any such statement is based except as required by law contact frank taffy cofounder president ceo and board member helocyte inc  gansevoort street th floor new york ny  phone  ● email frankhelocytecom related articles other press releases by helocyte inc data from phase  trial of triplex vaccine for control of cytomegalovirus published in blood october    profile helocyte inc   subscribe via rss  subscribe via atom  javascript new york new york united states contact data contact frank taffy cofounder president ceo and board member helocyte inc  gansevoort street th floor new york ny  phone  ● email frankhelocytecom contact with a reader account its easy to send email directly to the contact for this release sign up today for your free reader account already have an account log in here media files helocyte inc logo logo url  copy the link below formats available original medium small newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved business development – helocyte we are committed to strategic growth through targeted product acquisition the company actively pursues acquisition inlicensing  codevelopment and other partnering opportunities that are aligned with its internal areas of expertise and that enhance its pipeline learn more business development – helocyte we are committed to strategic growth through targeted product acquisition the company actively pursues acquisition inlicensing  codevelopment and other partnering opportunities that are aligned with its internal areas of expertise and that enhance its pipeline learn more contact us – helocyte for more information or business development inquiries please contact us via email at infohelocytecom helocyte inc  gansevoort street th floor new york ny  for job inquiries please send your resume to careershelocytecom about us – helocyte helocyte inc “helocyte” a portfolio company of fortress biotech is focused on the development and commercialization of novel immunotherapies for the prevention and treatment of cytomegalovirus “cmv” we aim to  secure rights to new technologies via acquisition licensing codevelopment andor other partnering  fund research and development of new technologies and  ultimately introduce new technologies to market we are currently progressing three immunotherapies developed in the laboratory of donald j diamond phd chair of the department of experimental therapeutics at city of hope of duarte california “city of hope” in march of  helocyte consummated an exclusive worldwide license and option agreement with city of hope acquiring rights to the current helocyte programs pepvax is an hlarestricted single antigen ul pp peptide vaccine for controlling cmv in allogeneic hematopoietic stem cell transplant “hsct” recipients in july of  we opened a phase  study of pepvax in allogeneic hsct recipients our second program triplex is a universal nonhlarestricted recombinant viral vector vaccine expressing three immunodominant proteins ul pp ul ie ul ie linked to cmv in the posttransplant setting in november of  we opened a phase  study of triplex in allogeneic hsct recipients we additionally plan to study triplex in recipients of allogeneic solid organ transplantation our third program pentamer is a universal nonhlarestricted recombinant viral vector vaccine expressing five primary subunits of cmv ghglululula linked to viral transmission in utero the pentamer program is currently undergoing nonclinical development and will ultimately be studied for prevention of congenital cmvhelocyte is headquartered in new york city management team – helocyte lindsay a rosenwald md executive chairman of the board of directors dr rosenwald has served as our executive chairman of the board of directors since inception dr rosenwald has been a member of the board of directors of fortress since october  and has served as its chairman president and chief executive officer since december   dr rosenwald also is coportfolio manager and partner of opus point partners llc an asset management firm in the life sciences industry which he cofounded in  prior to that from  to  he served as the chairman of paramount biocapital inc over the last  years dr rosenwald has acted as a biotechnology entrepreneur and has been involved in the founding and recapitalization of numerous public and private biotechnology and life sciences companies dr rosenwald received his bs in finance from pennsylvania state university and his md from temple university school of medicine   frank taffy jd cofounder president chief executive officer and director mr taffy has served as our president and chief executive officer since june of  and since december of  as a director of the board of helocyte mr taffy has over fifteen years of experience in life sciences corporate development and business operations he identified the helocyte programs and cofounded the company during his role as entrepreneur in residence at fortress biotech mr taffy previously held the positions of head senior director of business affairs at forest labs now allergan plc and director of corporate development at life technologies now thermo fisher scientific where he also held board positions on behalf of the company he also previously served as vice president and general counsel of paramount biosciences llc a global healthcare investment firm where he led the formation and interim operation of a number of portfolio companies mr taffy started his career as counsel for intellectual property at the procter and gamble company he holds a ba in biochemistry from the university of north texas and a jd from syracuse university college of law   david j horin interim chief financial officer mr horin has been a managing partner of chord advisors llc “chord” since june  chord provides accounting advisory services sec reporting advisory services and iporeadiness services pursuant to an agreement with chord dated june   mr horin is serving as our interim cfo while at chord mr horin has gained extensive experience in financial accounting and sec reporting for complex business transactions and issues arising from the application of existing or proposed financial accounting guidance from march  to june  mr horin was the chief financial officer of rodman  renshaw capital group inc a fullservice investment bank dedicated to providing corporate finance strategic advisory sales and trading and related services to public and private companies across multiple sectors and regions from march  through march  mr horin was the chief accounting officer at jefferies group inc a fullservice global investment bank and institutional securities firm focused on growth and middlemarket companies and their investors prior to his employment at jefferies group inc from  to  mr horin was a senior manager in kpmg’s department of professional practice in new york where he advised firm members and clients on technical accounting and risk management matters for a variety of public international and early growth stage entities mr horin has a bachelor of science degree in accounting from baruch college city university of new york mr horin is also a certified public accountant   elizabeth clark moore ms executive vice president of regulatory affairs ms moore has served as our executive vice president of regulatory affairs since may  she has over thirty years of experience in strategic regulatory registration and product development management of fda and global health authority interactions and completion of regulatory and other due diligence for acquisition targets ms moore started her career at the national institutes of health “nih” having served eight years with posts at both the national institute of allergy and infectious diseases and the national cancer institute her industry experience spans traditional pharmaceutical companies as well as biotech startups following her tenure at the nih ms moore joined agouron pharmaceuticals as director regulatory affairs for oncology development subsequent to the pfizerwarner lambert acquisition of agouron ms moore was appointed regulatory affairs site head senior director of pfizer global rd in la jolla ca for the past fifteen years ms moore has directed global regulatory affairs strategy and operations for both public and private companies holding seniorlevel positions at coronado biosciences now fortress paramount biosciences tracon pharmaceuticals salmedix acquired by cephalon and most recently fate therapeutics ms moore received her bs in pharmacy from the university of georgia and ms in administrative science from the johns hopkins university helocyte – a fortress biotech company helocyte inc “helocyte” a portfolio company of fortress biotech inc is focused on the development and commercialization of novel immunotherapies for the prevention and treatment of cancer and infectious disease in particular cytomegalovirus or “cmv” press releases october   data from phase  trial of triplex vaccine for control of cytomegalovirus published in blood april   helocyte announces corporate and clinical milestones april   fortress biotech fka coronado biosciences forms new subsidiary helocyte inc fka diavax biosciences to develop novel immunotherapies for cytomegalovirus pipeline